Early Complications of Radioisotope Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms—A Preliminary Study
Neuroendocrine neoplasms (NENs) constitute a heterogenous group of tumors originating from neuroendocrine cells scattered throughout the body. Peptide Receptor Radionuclide Therapy (PRRT) is a treatment of choice of unresectable metastasized progressive and well-differentiated NENs. The aim of the s...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/11/4/919 |
| _version_ | 1797479162718453760 |
|---|---|
| author | Barbara Bober Marek Saracyn Kornelia Zaręba Arkadiusz Lubas Paweł Mazurkiewicz Ewelina Wilińska Grzegorz Kamiński |
| author_facet | Barbara Bober Marek Saracyn Kornelia Zaręba Arkadiusz Lubas Paweł Mazurkiewicz Ewelina Wilińska Grzegorz Kamiński |
| author_sort | Barbara Bober |
| collection | DOAJ |
| description | Neuroendocrine neoplasms (NENs) constitute a heterogenous group of tumors originating from neuroendocrine cells scattered throughout the body. Peptide Receptor Radionuclide Therapy (PRRT) is a treatment of choice of unresectable metastasized progressive and well-differentiated NENs. The aim of the study was to assess early bone marrow and kidney injury after administration of Lutetium-177 or Lutetium-177 combined with Yttrium-90. Thirty-one patients received treatment with [<sup>177</sup>Lu]Lu-DOTATATE with the activity of 7.4 GBq. Eleven patients received tandem treatment with [<sup>90</sup>Y]Y-DOTATATE with the activity of 1.85 GBq + [<sup>177</sup>Lu]Lu-DOTATATE with the activity of 1.85 GBq. After PRRT a significant decrease in leukocyte, neutrophil, and lymphocyte counts was noted. Tandem treatment demonstrated a more marked decrease in white blood cell count compared to Lutetium-177 therapy only. Conversely, no significant influence on glomerular filtration was found in this assessment. However, PRRT triggered acute renal tubule dysfunction, regardless of the treatment type. Regarding the acute complications, PRRT appeared to be a safe modality in the treatment of patients with NEN. |
| first_indexed | 2024-03-09T21:42:11Z |
| format | Article |
| id | doaj.art-73607587e7c14939bb92d760e78bae9c |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-09T21:42:11Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-73607587e7c14939bb92d760e78bae9c2023-11-23T20:28:56ZengMDPI AGJournal of Clinical Medicine2077-03832022-02-0111491910.3390/jcm11040919Early Complications of Radioisotope Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms—A Preliminary StudyBarbara Bober0Marek Saracyn1Kornelia Zaręba2Arkadiusz Lubas3Paweł Mazurkiewicz4Ewelina Wilińska5Grzegorz Kamiński6Department of Endocrinology and Isotope Therapy, Military Institute of Medicine, 04-141 Warsaw, PolandDepartment of Endocrinology and Isotope Therapy, Military Institute of Medicine, 04-141 Warsaw, PolandFirst Department of Obstetrics and Gynecology, Centre of Postgraduate Medical Education, 01-813 Warsaw, PolandDepartment of Internal Diseases, Nephrology and Dialysis, Military Institute of Medicine, 04-141 Warsaw, PolandLaboratory of Ethology, Nencki Institute of Experimental Biology PAS, 02-093 Warsaw, PolandDepartment of Medical Diagnostics, Military Institute of Medicine, 04-141 Warsaw, PolandDepartment of Endocrinology and Isotope Therapy, Military Institute of Medicine, 04-141 Warsaw, PolandNeuroendocrine neoplasms (NENs) constitute a heterogenous group of tumors originating from neuroendocrine cells scattered throughout the body. Peptide Receptor Radionuclide Therapy (PRRT) is a treatment of choice of unresectable metastasized progressive and well-differentiated NENs. The aim of the study was to assess early bone marrow and kidney injury after administration of Lutetium-177 or Lutetium-177 combined with Yttrium-90. Thirty-one patients received treatment with [<sup>177</sup>Lu]Lu-DOTATATE with the activity of 7.4 GBq. Eleven patients received tandem treatment with [<sup>90</sup>Y]Y-DOTATATE with the activity of 1.85 GBq + [<sup>177</sup>Lu]Lu-DOTATATE with the activity of 1.85 GBq. After PRRT a significant decrease in leukocyte, neutrophil, and lymphocyte counts was noted. Tandem treatment demonstrated a more marked decrease in white blood cell count compared to Lutetium-177 therapy only. Conversely, no significant influence on glomerular filtration was found in this assessment. However, PRRT triggered acute renal tubule dysfunction, regardless of the treatment type. Regarding the acute complications, PRRT appeared to be a safe modality in the treatment of patients with NEN.https://www.mdpi.com/2077-0383/11/4/919neuroendocrine neoplasmtreatment of neuroendocrine neoplasmPRRT |
| spellingShingle | Barbara Bober Marek Saracyn Kornelia Zaręba Arkadiusz Lubas Paweł Mazurkiewicz Ewelina Wilińska Grzegorz Kamiński Early Complications of Radioisotope Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms—A Preliminary Study Journal of Clinical Medicine neuroendocrine neoplasm treatment of neuroendocrine neoplasm PRRT |
| title | Early Complications of Radioisotope Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms—A Preliminary Study |
| title_full | Early Complications of Radioisotope Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms—A Preliminary Study |
| title_fullStr | Early Complications of Radioisotope Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms—A Preliminary Study |
| title_full_unstemmed | Early Complications of Radioisotope Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms—A Preliminary Study |
| title_short | Early Complications of Radioisotope Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms—A Preliminary Study |
| title_sort | early complications of radioisotope therapy with lutetium 177 and yttrium 90 in patients with neuroendocrine neoplasms a preliminary study |
| topic | neuroendocrine neoplasm treatment of neuroendocrine neoplasm PRRT |
| url | https://www.mdpi.com/2077-0383/11/4/919 |
| work_keys_str_mv | AT barbarabober earlycomplicationsofradioisotopetherapywithlutetium177andyttrium90inpatientswithneuroendocrineneoplasmsapreliminarystudy AT mareksaracyn earlycomplicationsofradioisotopetherapywithlutetium177andyttrium90inpatientswithneuroendocrineneoplasmsapreliminarystudy AT korneliazareba earlycomplicationsofradioisotopetherapywithlutetium177andyttrium90inpatientswithneuroendocrineneoplasmsapreliminarystudy AT arkadiuszlubas earlycomplicationsofradioisotopetherapywithlutetium177andyttrium90inpatientswithneuroendocrineneoplasmsapreliminarystudy AT pawełmazurkiewicz earlycomplicationsofradioisotopetherapywithlutetium177andyttrium90inpatientswithneuroendocrineneoplasmsapreliminarystudy AT ewelinawilinska earlycomplicationsofradioisotopetherapywithlutetium177andyttrium90inpatientswithneuroendocrineneoplasmsapreliminarystudy AT grzegorzkaminski earlycomplicationsofradioisotopetherapywithlutetium177andyttrium90inpatientswithneuroendocrineneoplasmsapreliminarystudy |